Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jagsonpal Pharmaceuticals Ltd. ( (IN:JAGSNPHARM) ) has provided an update.
Jagsonpal Pharmaceuticals Ltd. announced that its Board of Directors has approved the unaudited financial results for the quarter and nine-month period ended December 31, 2025. The results, which have undergone a limited review by the company’s statutory auditors in line with Indian Accounting Standards and SEBI’s listing regulations, mark a key disclosure for investors and regulators, reinforcing ongoing compliance with financial reporting norms and providing stakeholders with updated visibility on the company’s financial performance for the current fiscal year to date.
More about Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Ltd. is an India-based pharmaceutical company engaged in the development, manufacture and marketing of pharmaceutical products, serving the domestic healthcare market from its offices in Gurugram, New Delhi and Mumbai.
Average Trading Volume: 3,732
Technical Sentiment Signal: Hold
Current Market Cap: 11.64B INR
For detailed information about JAGSNPHARM stock, go to TipRanks’ Stock Analysis page.